Fresenius reports Q3 beat thanks to Kabi growth in emerging markets

Credit: REUTERS/RALPH ORLOWSKI

German healthcare group Fresenius beat third-quarter revenue forecasts on Tuesday as softer revenue growth in North America was offset by growth of its infusions drugs unit Kabi in emerging markets.

Oct 29 (Reuters) - German healthcare group Fresenius FREG.DE beat third-quarter revenue forecasts on Tuesday as softer revenue growth in North America was offset by growth of its infusions drugs unit Kabi in emerging markets.

The group confirmed its full-year guidance after third-quarter revenues rose by 8% to 8.9 billion euros in the third quarter, compared to 8.7 billion euros in a company-compiled consensus.

(Reporting by Zuzanna Szymanska in Gdansk Editing by Tomasz Janowski)

((zuzanna.szymanska@thomsonreuters.com; + 48 58 778 52 86;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More